RHJA
AUPH icon

Rice Hall James & Associates’s Aurinia Pharmaceuticals AUPH Stock Holding History

Rice Hall James & Associates’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.23M Sell
487,898
-7,738
-2% -$113K 0.4% 65
2025
Q4 		$7.91M Sell
495,636
-46,919
-9% -$665K 0.44% 61
2025
Q3 		$6M Sell
542,555
-7,946
-1% -$86.8K 0.33% 75
2025
Q2 		$4.66M Buy
550,501
+325,031
+144% +$2.61M 0.25% 85
2025
Q1 		$1.81M Buy
+225,470
New +$1.83M 0.11% 168

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Rice Hall James & Associates's AUPH Position: Q1 2026 in Review

Rice Hall James & Associates reduced its Aurinia Pharmaceuticals (AUPH) stake by 1.6% in Q1 2026, selling an estimated $113K and leaving 487,898 shares worth $7.23M. The position accounts for 0.4% of the portfolio, ranked #65.

Rice Hall James & Associates first reported a position in AUPH in Q1 2025 and has held it in 5 quarters since. The position peaked at $7.91M in Q4 2025. 259 funds tracked by Wall St. Rank hold AUPH as of Q1 2026.

  • Rice Hall James & Associates held 487,898 shares of Aurinia Pharmaceuticals worth $7.23M as of Q1 2026.
  • Rice Hall James & Associates sold 7,738 Aurinia Pharmaceuticals shares in Q1 2026, an estimated $113K.
  • Aurinia Pharmaceuticals made up 0.4% of Rice Hall James & Associates's portfolio in Q1 2026, its #65 holding.
  • Rice Hall James & Associates first reported a position in Aurinia Pharmaceuticals in Q1 2025 and has held it in 5 quarters since.
  • Rice Hall James & Associates's Aurinia Pharmaceuticals position peaked at $7.91M in Q4 2025.
  • 259 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q1 2026.

Based on Rice Hall James & Associates's 13F filing for Q1 2026, filed 15 May 2026.